Ocean Biomedical, Inc.
Ocean Biomedical, Inc. is a U.S.-based biopharmaceutical company focused on discovering and developing drug candidates in oncology, fibrosis, and infectious disease. Its business centers on advancing preclinical and clinical-stage programs, protecting intellectual property, and, if successful, moving candidates through regulatory approval toward commercialization or licensing.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2021–2024
Liiketoiminta
Osuus liikevaihdostaDiscovery-stage therapeutic assets being advanced through research and early development.
Drug candidates in human trials across oncology, fibrosis, and infectious disease.
Work to produce drug material and prepare late-stage and commercial manufacturing processes.
Potential out-licensing or collaboration structures tied to product candidates and IP.
Patent and know-how assets supporting candidate development and partnering value.
Asiakkaat
Ocean Biomedical does not currently sell commercial products, so its near-term counterparties are research institutions, contract manufacturers, clinical service providers, and potential licensing partners. If product candidates are approved, the company would ultimately serve physicians, hospitals, and other healthcare providers through commercial drug sales or partners. The business model also depends on universities and medical centers that contribute research assets and scientific collaboration.
Provide licensed discoveries, scientific collaboration, and translational research support.
Manufacture preclinical and clinical drug material and support process development.
Trial sites, CROs, and service providers that execute preclinical and clinical studies.
Pharmaceutical partners that may license assets or help commercialize approved products.
End users of approved therapies in oncology, fibrosis, or infectious disease.
Strategia
The company’s strategy is to advance a pipeline of oncology, fibrosis, and infectious disease candidates from preclinical work into clinical testing and, if successful, through regulatory approval. It also aims to build manufacturing, commercialization, and intellectual property capabilities so it can either launch products itself or monetize assets through licensing partnerships.
Clinical entry is the key value-creation step for a pre-commercial biotech company.
Approval is required before any candidate can be sold or broadly commercialized.
Late-stage development requires reliable supply and a path to market.
Patent protection supports partnering leverage and future exclusivity.
Maantiede
Ocean Biomedical is headquartered in the United States and operates as a U.S. public biotechnology company. Its development work is organized around research, clinical development, manufacturing, and regulatory activities that may involve U.S.-based and global third-party partners, but no country-level revenue is disclosed because the company has not generated product revenue.
Riskit
Ocean Biomedical faces the typical risks of an early-stage biotechnology company: its candidates may fail in preclinical or clinical development, regulatory approval may not be obtained, and commercialization may never occur. The company also carries meaningful financing and dilution risk because development, manufacturing, and regulatory work require substantial capital before any product revenue is generated.
- Financing and liquidity riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has no product revenue and depends on external capital to fund operations.
Kohdistuu - Debt and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Outstanding convertible notes and warrants can pressure cash needs and share count.
Kohdistuu: Convertible debt and equity-linked financing
- Clinical and development failureVaikutus: Korkea
Therapeutic candidates must succeed through preclinical and clinical testing before approval.
Kohdistuu - Regulatory approval riskVaikutus: Korkea
Even promising candidates require successful regulatory review before commercialization.
Kohdistuu: All product candidates
- Intellectual property riskVaikutus: Keskitaso
Value depends on obtaining and protecting patents and licensed rights.
Kohdistuu: Licensed assets and proprietary technology
Kirjanpito
Harkinnanvaraiset erätThese instruments can require fair value estimates and may create dilution or non-cash gains/losses.
Vaikutus: Can materially affect liabilities, equity, and reported earnings
Complex financing features require valuation assumptions that can change period to period.
Vaikutus: May create volatility in other income/expense
Most development costs are expensed as incurred, affecting operating loss timing.
Vaikutus: Drives reported burn and comparability across periods
The company estimates costs for services received but not yet invoiced.
Vaikutus: Can shift expenses between periods
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Oragenics Inc
OGEN · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Päivitetty: 24.9.2026